Trump plans to ease access to psychedelics like psilocybin, ibogaine

President Donald Trump is planning to sign an executive order on Saturday to boost research into psychedelics and potentially make the drugs available in controlled therapeutic environments, according to three people who spoke on the condition of anonymity to discuss the administration’s plans.
Trump’s planned order will direct new steps from the Food and Drug Administration, which regulates drug safety. The agency would issue new guidance to researchers on how to design clinical trials for drugs such as psilocybin, ibogaine and other serotonin receptors. Those drugs, which also include LSD and MDMA, can cause hallucinogenic effects and are illegal in the United States.